Unleash the power of cutting-edge immunotherapy to safeguard against HCMV with Dense Immune’s innovative Dense Bodies.
Discover MoreWe are committed to reshaping the future of HCMV defense with pioneering immunotherapy, harnessing bioengineered Dense Bodies to enhance global well-being.
Tackling HCMV challenges that impact millions through transplantation and congenital cases globally.
Backed by a robust intellectual property portfolio spanning multiple continents.
Crafting safe, highly immunogenic therapeutic platforms free of infectious agents.
Dense Immune’s Dense Bodies deliver over 40 antigens in a non-infectious format, sparking powerful immune responses without additional boosters.
CEO & Co-Founder, Virology Specialist
Chief Medical Officer, Medical Expert, Co-Founder
Virology Expert, Co-Founder
Research & Development, Co-Founder
Initiate toxicology studies for HSCT patients.
File Clinical Trial Application (CTA).
Complete GMP certification for manufacturing.
Begin Phase I clinical trials.
Progress to Phase II clinical trials.
Secured funding to support early development.
€1.05M
Established as a pre-incorporated entity.
Foundation Laid
Seeking funds for production readiness.
€800K of €2M
Planning Series A funding round for clinical trial.
TBD
€800K of €2M in Seed Investment (Awaiting Due Diligence)
Partner with Dense Immune to redefine HCMV protection. Reach out for collaborations, investments, or questions.
Start the Conversation